Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates

IF 40.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Signal Transduction and Targeted Therapy Pub Date : 2024-11-20 DOI:10.1038/s41392-024-02058-x

Leonie Mayer, Leonie M. Weskamm, Marylyn M. Addo

引用次数: 0

Abstract

In a recent study published in Cell, Mucker et al. demonstrated in a non-human primate (NHP) model of lethal mpox virus (MPXV) infection, that a novel mRNA-based vaccine, as compared to the standard-of-care modified vaccinia virus Ankara (MVA) vaccine, provides similar protective efficacy against lethality but superior efficacy against disease.¹ In the mRNA-vaccinated group, a reduction in the number of lesions and viremia was associated with both neutralizing and Fc-mediated antibody functionality.

Abstract Image

查看原文本刊更多论文

下一代 mpox 疫苗：mRNA-1769 与改良安卡拉疫苗病毒在非人灵长类动物中的功效比较

在最近发表于《细胞》（Cell）的一项研究中，Mucker 等人在非人灵长类（NHP）致死性 mpox 病毒（MPXV）感染模型中证实，与标准护理型改良安卡拉疫苗（MVA）相比，基于 mRNA 的新型疫苗具有类似的致死保护效力，但对疾病的疗效更优1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Signal Transduction and Targeted Therapy Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

44.50

自引率

1.50%

发文量

384

审稿时长

5 weeks

期刊介绍： Signal Transduction and Targeted Therapy is an open access journal that focuses on timely publication of cutting-edge discoveries and advancements in basic science and clinical research related to signal transduction and targeted therapy. Scope: The journal covers research on major human diseases, including, but not limited to: Cancer,Cardiovascular diseases,Autoimmune diseases,Nervous system diseases.